Cetuximab (added to chemotherapy, RAS Wild-Type)
Treatment for Colon and rectum cancer
Typical Dosage: Initial 400 mg/m2 IV, then 250 mg/m2 IV weekly (with chemotherapy)
Effectiveness
75%
Safety Score
35%
Clinical Trials
150
Participants
20K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
35
DangerousModerateSafe
Treatment Details
Dosage Range
Initial 400 mg/m2 IV, then 250 mg/m2 IV weekly (with chemotherapy)
Time to Effect
1-3 months
Treatment Duration
Until progression
Evidence Quality
HIGHNumber Needed to Treat (NNT)
8(Treat 8 patients to see 1 additional successful outcome)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$95,000
Monitoring:$17,000
Side Effect Mgmt:$15,000
Total Annual:$127,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$115,000/QALY
QALYs Gained
0.2
Outcome-Based Costs
Cost per Responder
$211,667
Cost per Remission
$2,540,000
Comparison vs FOLFIRI
Cost Difference
+$87,000/year
More expensive
QALY Difference
+0.20 QALYs
Better outcomes
Dominance
No dominance
Cetuximab (added to chemotherapy, RAS Wild-Type) Outcomes
for Colon and rectum cancer
Efficacy Outcomes
Overall Effectiveness
+75%
Response Rate
+60%
Remission Rate
+5%
Common Side Effects
Acne-like rash
+85%
Hypomagnesemia
+60%
Fatigue
+40%
Diarrhea
+25%
Infusion reactions
+4%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov